[144] NetFlix Inc SEC Filing

Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) filed a Form 8-K on August 6, 2025. Under Item 2.02, the company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is expressly not deemed “filed” for liability purposes under Section 18 of the Exchange Act. Item 9.01 lists the exhibits included in the filing, namely the press release and the cover-page Inline XBRL data file. No actual financial figures, guidance, or narrative commentary are contained within the 8-K itself.

The filing is procedural, serving mainly to make the earnings release publicly available while limiting legal exposure. Investors must review Exhibit 99.1 for quantitative details.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishes Q2-25 earnings release; no numbers disclosed here.

The 8-K is purely administrative, triggering no immediate valuation insight because it omits the underlying financial metrics. Management uses Item 2.02 to ensure Reg FD compliance while keeping the furnished material outside Section 18 liability. Impact on the stock will depend entirely on the content of Exhibit 99.1, which is not provided. Therefore, the filing itself is neutral and non-impactful from an analytical standpoint.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	238	274537.76	424926346	08/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/04/2025	Restricted Stock	Issuer			238	08/04/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CLETUS WILLEMS 121 Albright Way Los Gatos CA 95032	Common	05/07/2025	298	339124.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Why did Artiva Biotherapeutics (ARTV) file a Form 8-K on August 6, 2025?

To furnish its press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02.

Does the 8-K include Artiva’s Q2 2025 financial numbers?

No. The filing references the press release as Exhibit 99.1, but no figures appear in the body of the 8-K.

Is the furnished press release considered "filed" with the SEC?

No. Artiva states the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.

What exhibits accompany the 8-K?

Exhibit 99.1 (press release dated August 6, 2025) and Exhibit 104 (cover-page Inline XBRL data file).

How should investors obtain the actual earnings details?

Investors need to read Exhibit 99.1, which contains the full Q2 2025 financial results.